Citi lowered the firm’s price target on Health Catalyst (HCAT) to $2.75 from $3.25 and keeps a Neutral rating on the shares as part of the firm’s 2026 outlook note on the health tech and distribution group. 2025 proved to be another challenging year for health tech, with nearly one-third of the group down greater than 25%, but the firm is “cautiously optimistic” looking ahead to 2026, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCAT:
- Health Catalyst Appoints New Board Member Matt Arens
- Health Catalyst Q3 2025 Earnings: Mixed Sentiment and Strategic Focus
- Health Catalyst price target lowered to $3.75 from $4.50 at Stifel
- Health Catalyst price target lowered to $5 from $6 at Wells Fargo
- Health Catalyst: Buy Rating Affirmed Amid Strong Financial Performance and Promising Future Prospects